One To Watch

Immatics

Company Overview

A clinical-stage biopharmaceutical company developing T-cell redirecting cancer immunotherapies, with the broadest clinical PRAME franchise spanning TCR bispecifics and TCR-based cell therapies across more than 50 tumor types. Immatics N.V. (NASDAQ: IMTX) operates across two complementary modalities: off-the-shelf TCR bispecifics, branded TCER, and personalized TCR T-cell therapies. The pipeline is concentrated on cancer-testis antigens, particularly PRAME and MAGEA4/8, which are broadly expressed across solid tumors yet largely absent from healthy adult tissue. That target specificity is the commercial and scientific thesis underpinning the company's strategy.

Headquarters and Global Presence

Immatics maintains dual headquarters in Tuebingen, Germany and Houston, Texas. The German base houses its founding scientific infrastructure, while the Houston operation anchors its US clinical and commercial development activities. The company is listed on NASDAQ under the ticker IMTX.

Founding and History

Harpreet Singh co-founded Immatics in 2000 during his PhD studies. Singh was appointed CEO in July 2019, having previously served as President and CEO of Immatics US and as the company's Chief Scientific Officer. Over its history Immatics has drawn in major pharma collaborators including Bristol Myers Squibb, GSK, Celgene, Genmab, and Moderna, reflecting sustained external validation of its targeting approach, though several of those collaborations have since concluded.

Therapy Areas and Focus

Immatics focuses exclusively on oncology, targeting solid tumors where checkpoint inhibitors and conventional therapies have delivered limited benefit. Its programs address melanoma, lung cancer, head and neck cancer, gynecologic cancers, and other PRAME-expressing malignancies. The clinical rationale rests on engaging cytotoxic T cells directly against HLA-presented intracellular tumor antigens, a class of targets inaccessible to antibody-based therapies.

Technology Platforms and Modalities

The TCER platform generates bispecific molecules that redirect endogenous T cells by recognizing HLA-peptide complexes on tumor cells, without requiring patient-derived cell engineering. This distinguishes TCER from autologous cell therapy, offering a scalable, off-the-shelf format with a faster path to broad patient access. In parallel, Immatics advances autologous TCR T-cell therapies where deeper, durable responses are the goal.

The combination of both modalities against shared targets such as PRAME creates the possibility of sequential or concurrent dosing strategies, a rationale the company is actively testing in squamous non-small cell lung cancer.

Key Pipeline and Programs

IMA401 is a TCER bispecific targeting MAGEA4/8, currently in Phase I development in heavily pretreated patients with solid tumors including head and neck and lung cancer. At its recommended Phase II dose, IMA401 has shown a consistent, favorable tolerability profile and encouraging anti-tumor activity. Data were presented at the 2026 ASCO Annual Meeting with simultaneous publication in Nature Medicine, a peer validation that meaningfully raises the asset's profile.

IMA402 is a TCER bispecific targeting PRAME, advancing into Phase Ib dose expansion as monotherapy and in combination with an immune checkpoint inhibitor, with melanoma and gynecologic cancers as priority indications. Immatics is also exploring an IMA401/IMA402 combination regimen in squamous non-small cell lung cancer, which would be the first dual-TCER dosing strategy in clinical testing.

IMA203 (anzutresgene autoleucel, anzu-cel) is an autologous TCR T-cell therapy targeting PRAME.

Recent Developments

In August 2026, Immatics priced a $150 million underwritten offering at $8.69 per share, with Jefferies, Leerink Partners, and Cantor acting as joint book-running managers; the offering was expected to close on August 26, 2026. The August 2026 raise at a lower price reflects ongoing cash needs as two bispecifics advance through Phase I and into Phase Ib expansion. The IMA401 ASCO 2026 dataset, published simultaneously in Nature Medicine, was the most material clinical milestone of the past twelve months.

Key Personnel

Harpreet Singh serves as Chief Executive Officer. Singh co-founded Immatics in 2000 during his PhD, has led the company as CEO since July 2019, and previously held the roles of President and CEO of Immatics US and Chief Scientific Officer.

Strategic Partnerships

Immatics has also previously collaborated with Genmab and MorphoSys. The Moderna partnership now stands as the company's primary active external collaboration.

FAQ Section

PRAME is expressed in more than 50 cancer types but is largely absent from healthy adult tissue, making it an attractive target for T-cell-based therapies where on-tumor selectivity determines the therapeutic window. Immatics has built its clinical pipeline explicitly around this target, fielding both a TCR bispecific (IMA402) and an autologous cell therapy (IMA203) against PRAME, an approach that allows the company to generate data across multiple modalities and indications from a single antigen franchise. The breadth of PRAME expression also gives the commercial addressable population a scale that narrower targets cannot match.

Conventional bispecific antibodies can only engage antigens displayed on the cell surface, but most tumor-specific proteins, including PRAME and MAGEA4/8, are intracellular. TCR bispecifics like Immatics' TCER molecules work by recognizing short peptide fragments of those intracellular proteins presented on HLA molecules, the same recognition mechanism used by natural T cells. This unlocks a much larger space of cancer-specific targets that antibody modalities simply cannot reach, which is the fundamental differentiating premise of the TCER platform.

TCER bispecifics such as IMA401 and IMA402 are manufactured centrally and administered without patient-specific engineering, making them scalable and logistically simpler than autologous cell therapies such as anzu-cel, which require extracting and re-engineering each patient's own T cells. Autologous approaches can deliver deeper, more durable responses in some settings, which is why Immatics continues to advance both modalities rather than consolidating on one. The emerging combination strategy, testing IMA401 and IMA402 together in squamous non-small cell lung cancer, is an attempt to generate complementary anti-tumor activity while retaining the manufacturing simplicity of the off-the-shelf format.

IMA401, targeting MAGEA4/8, demonstrated a consistent, favorable tolerability profile and encouraging anti-tumor activity at its recommended Phase II dose in heavily pretreated patients with head and neck and lung cancer. Simultaneous publication in Nature Medicine at ASCO 2026 is an endorsement of data quality and signals the company is building the scientific case for a Phase II expansion, particularly in combination with IMA402 in squamous non-small cell lung cancer.

Melanoma, both cutaneous and uveal, is the most advanced indication, with anzu-cel holding FDA RMAT designation across multiple PRAME-expressing tumor types including uveal melanoma and ovarian cancer. Head and neck cancer and lung cancer, particularly squamous non-small cell lung cancer, are the priority solid tumor indications for IMA401 and the combination program. Gynecologic cancers feature prominently in the IMA402 Phase Ib expansion alongside melanoma, reflecting the broad PRAME expression profile across these histologies.

Immatics is a clinical-stage company with its most advanced programs in Phase I and transitioning into Phase Ib expansion. IMA203 holds RMAT designation, which provides accelerated FDA interaction and could compress the path to a Phase II or registrational study.

The watchpoints for Immatics center on clinical data readouts, capital deployment, and partnership dynamics:

Phase Ib dose-expansion data for IMA402 in melanoma and gynecologic cancers, including early signals from the checkpoint inhibitor combination, are the most proximate clinical catalyst.
Proof-of-concept data from the dual IMA401/IMA402 combination in squamous non-small cell lung cancer would be a genuinely novel readout, with no precedent for concurrent TCER dosing in the clinic.
The Moderna collaboration is currently the sole active major external partnership; failure to attract a replacement for the departed BMS and GSK agreements would concentrate both financial and reputational risk on Immatics alone.
Two dilutive equity raises in under twelve months at declining share prices signal ongoing cash burn; the runway delivered by the $150 million August 2026 raise will be a key question for investors.
RMAT designation for anzu-cel accelerates FDA dialogue, but regulatory progress in autologous cell therapy remains complex and costly to manufacture at scale.

Want to Update your Company's Profile?